SentenceIn 2025, we announced that Alvotech had entered into a collaboration and license agreement with Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") to co-develop, manufacture and commercialize a biosimilar to Keytruda for global markets.

ALVO 20-Faccession 0001898416-26-000004filed Mar 31 '26ALVO

COYACoya Therapeutics, Inc.

SentenceBoth parties shall discuss in good faith and agree in writing on the terms of a commercial supply agreement for the purpose of supply of COYA 302 to Dr. Reddy's.

COYA 10-Kaccession 0001193125-26-107281filed Mar 16 '26COYA

IMMPImmutep Ltd

SentenceThe Company received US$ 20 million (A$ 28.8 million) as an upfront license fee from Dr Reddy's in January 2026, of which US$ 2.7 million (A$ 4.1 million) was recognized as revenue and US$ 17.3 million (A$ 25.8 million) as unearned revenue in the Company's Half-Year Report at December 31, 2025.

IMMP 20-Faccession 0001193125-26-429413filed Oct 23 '26IMMP

RIGLRigel Pharmaceuticals Inc

SentenceIn addition, we recognized revenue from Grifols of $9.1 million related to delivery of drug supplies and earned royalty, and $4.0 million from Dr. Reddy's related to an upfront fee from sublicensing olutasidenib.

RIGL 10-Kaccession 0001558370-25-002169filed Mar 4 '25RIGL

customer

COYACoya Therapeutics, Inc.

SentencePursuant to the terms of the DRL Supply Agreement, we will in-license DRL's proposed abatacept biosimilar for use in the development of our combination product for neurodegenerative diseases COYA 302.

COYA 10-Kaccession 0001193125-26-107281filed Mar 16 '26COYA

CTORCitius Oncology, Inc.

Sentenceexclusive license of E7777 (denileukin diftitox), an oncology immunotherapy for the treatment of CTCL, from Dr. Reddy's, who had

Order: filed share, then A–Z, unlisted last

Methodology

ties · implied moves · holdersMethod

Ties Implied moves Holders

Dependency

Sources

Methodology

ties · implied moves · holdersMethod

Ties Implied moves Holders